Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment

Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI tr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:FEBS Open Bio
Glavni autori: Cao, Haixia, Yu, Shaorong, Chen, Dan, Jing, Changwen, Wang, Zhuo, Ma, Rong, Liu, Siwen, Ni, Jie, Feng, Jifeng, Wu, Jianzhong
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Research Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5221460/
https://ncbi.nlm.nih.gov/pubmed/28097086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12147
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items